open access

Vol 10, Supp. C (2019)
Case report
Get Citation

Treatment efficacy with brentuximab vedotin in the third-line therapy of primary refractory systemic anaplastic large cell lymphoma ALK(–)

Beata Kania-Zembaczyńska1
DOI: 10.5603/Hem.2019.0021
Affiliations
  1. Oddział Onkologiczny i Hematoonkologiczny, Beskidzkie Centrum Onkologii — Szpital Miejski, ul. Wyzwolenia 18, 43–382 Bielsko-Biała, Poland

open access

Vol 10, Supp. C (2019)
CASE REPORTS

Abstract

Anaplastic large cell lymphoma (ALCL) is rare hematological malignancy and subtype of mature T-cell lymphoma. Most patients with diagnosed systemic ALCL (sALCL) respond to common first-line chemotherapy based on antracycline (CHOP [doxorubicin, vincristine, prednisone], or CHOEP [doxorubicin, vincristine, etoposide, prednisone]). Long-term treatment results depends on a subtype and other prognostic factors. About 40–65% patients with ALCL ALK(–) develop reccurent disease. High-dose chemotherapy and autologous hematopoietic stem cell trasplantation improve outcome in this group of patients. Brentuximab vedotin has shown efficacy with relapsed sALCL and enable gaining objective respones in 86% of cases.

Abstract

Anaplastic large cell lymphoma (ALCL) is rare hematological malignancy and subtype of mature T-cell lymphoma. Most patients with diagnosed systemic ALCL (sALCL) respond to common first-line chemotherapy based on antracycline (CHOP [doxorubicin, vincristine, prednisone], or CHOEP [doxorubicin, vincristine, etoposide, prednisone]). Long-term treatment results depends on a subtype and other prognostic factors. About 40–65% patients with ALCL ALK(–) develop reccurent disease. High-dose chemotherapy and autologous hematopoietic stem cell trasplantation improve outcome in this group of patients. Brentuximab vedotin has shown efficacy with relapsed sALCL and enable gaining objective respones in 86% of cases.

Get Citation

Keywords

anaplastic large cell lymphoma, high-dose chemotherapy, brentuximab vedotin

About this article
Title

Treatment efficacy with brentuximab vedotin in the third-line therapy of primary refractory systemic anaplastic large cell lymphoma ALK(–)

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. C (2019)

Article type

Case report

Pages

21-25

DOI

10.5603/Hem.2019.0021

Keywords

anaplastic large cell lymphoma
high-dose chemotherapy
brentuximab vedotin

Authors

Beata Kania-Zembaczyńska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.